Phase 2 N=51 Autoantibody Reduction for Acute Exacerbations of Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis, Acute Fatal Form
Primary: %Survival — 44; 7 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=831 Study to Evaluate H56:IC31 in Preventing Rate of TB Recurrence
Tuberculosis, Pulmonary
Primary: Rate of TB Disease Recurrence (Relapse or Reinfection), Defined as TB Diagnosed by Confirmation of Mtb by Culture of Sputum. — 23; 14; 377; 392 Participants — p=0.9558
Phase 2 N=96 Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK-3773274 in Adults With Hypertrophic Cardiomyopathy
Hypertrophic Cardiomyopathy (HCM)
Primary: Incidence of Adverse Events (AEs) — 10; 7; 11; 4 Participants
Phase 2 N=96 Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab
Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma · Follicular Lymphoma
Primary: Part A: The Recommended Dose for Expansion (RDFE) of BGB-10188 Monotherapy in Hematologic Malignancies — NA mg
Phase 2 N=24 Open-Label Extension Study to Evaluate the Safety of Efgartigimod in Adult Patients With Primary Sjögren's Syndrome
Primary Sjögren's Syndrome
Primary: Number of Participants With TEAEs, TESAEs and TEAESIs — 15; 6; 0; 2 Participants
Phase 2 N=67 INRT-AIR: A Prospective Phase II Study of Involved Nodal Radiation Therapy
Head and Neck Squamous Cell Carcinoma
Primary: Risk of Solitary Elective Volume Recurrence Following Elective Volume Reduction Using INRT — 11; 9; 3; 6 percentage of participants
Phase 2 N=87 Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies
Hematologic Malignancies
Primary: Number of Participants Who Have Severe Acute Graft-versus-host-disease (GVHD) — 2; 0; 5; 1 Participants
Phase 2 N=91 Hypofractionated Adaptive Image-Guided Radiation Therapy for Localized Adenocarcinoma of the Prostate
Prostate Cancer
Primary: Number of Participants With Grade 2 or Greater GU and GI Toxicity — 9; 2; 1; 1 Participants
Phase 2 N=33 Discovery of Sirolimus Sensitive Biomarkers in Blood
Lymphangioleiomyomatosis
Primary: Number of Sirolimus-Sensitive Plasma Protein Biomarkers in Lymphangioleiomyomatosis (LAM) Participants — 662 plasma proteins
Phase 2 N=652 STARS (Smoking Treatment And Remote Sampling) Study
Smoking · Smoking Cessation · Tobacco Smoking
Primary: Smoking Cessation — 16.7; 8.1; 9.9 Percent
Phase 2 N=622 Single or Repeat Dose of G03-52-01 in Adult Subjects
Healthy · Botulinum Toxin
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 61; 61; 61; 56 Participants
Phase 2 N=82 Safety and Efficacy of RHH646 for Knee Osteoarthritis
Osteoarthritis, Knee
Primary: Change From Baseline in Cartilage Volume in the Index Region of the Target Knee by MRI — 94.6; 9.3 µL — p=0.0575
Phase 2 N=40 Visual Acoustic Biofeedback for RSE Via Telepractice
Speech Sound Disorder
Primary: Rhotic Accuracy (/r/) — 30.55; 28.60; 9.54; -.78 mean difference in percent correct
Phase 2 N=48 SH-DS01 on Fecal Metagenomic Stability
Irritable Bowel Syndrome
Primary: Safety and Tolerability of DS-01 Treatment vs Placebo — 0; 0 Participants
Phase 2 N=37 Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer
Breast Adenocarcinoma · Invasive Breast Carcinoma · Triple-Negative Breast Carcinoma
Primary: RCB Status — 12; 5; 20 Participants